In the past week, CATX stock has gone up by 31.35%, with a monthly decline of -1.62% and a quarterly plunge of -33.06%. The volatility ratio for the week is 8.54%, and the volatility levels for the last 30 days are 10.76% for Perspective Therapeutics Inc The simple moving average for the last 20 days is 20.39% for CATX stock, with a simple moving average of -68.30% for the last 200 days.
Is It Worth Investing in Perspective Therapeutics Inc (AMEX: CATX) Right Now?
CATX has 36-month beta value of 1.10. Analysts have mixed views on the stock, with 10 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CATX is 53.81M, and currently, short sellers hold a 10.61% ratio of that float. The average trading volume of CATX on April 25, 2025 was 759.55K shares.
CATX) stock’s latest price update
Perspective Therapeutics Inc (AMEX: CATX) has seen a rise in its stock price by 4.29 in relation to its previous close of 2.33. However, the company has experienced a 31.35% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-23 that SEATTLE, April 23, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that data on the Company’s [212Pb]VMT-α-NET and [212Pb]VMT01 programs have been accepted for presentation as detailed below at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3, 2025 in Chicago, Illinois. ASCO plans to release further details for regular abstracts on May 22, 2025 at 5:00 PM EDT.
Analysts’ Opinion of CATX
Many brokerage firms have already submitted their reports for CATX stocks, with H.C. Wainwright repeating the rating for CATX by listing it as a “Buy.” The predicted price for CATX in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on March 13, 2025 of the current year 2025.
Scotiabank, on the other hand, stated in their research note that they expect to see CATX reach a price target of $15. The rating they have provided for CATX stocks is “Sector Outperform” according to the report published on March 07th, 2025.
BofA Securities gave a rating of “Neutral” to CATX, setting the target price at $5 in the report published on November 25th of the previous year.
CATX Trading at 1.47% from the 50-Day Moving Average
After a stumble in the market that brought CATX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.24% of loss for the given period.
Volatility was left at 10.76%, however, over the last 30 days, the volatility rate increased by 8.54%, as shares surge +7.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.61% lower at present.
During the last 5 trading sessions, CATX rose by +31.35%, which changed the moving average for the period of 200-days by -77.83% in comparison to the 20-day moving average, which settled at $2.02. In addition, Perspective Therapeutics Inc saw -23.82% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CATX starting from Spoor Johan M., who purchase 22,026 shares at the price of $2.24 back on Mar 28 ’25. After this action, Spoor Johan M. now owns 59,383 shares of Perspective Therapeutics Inc, valued at $49,384 using the latest closing price.
Spoor Johan M., the Chief Executive Officer of Perspective Therapeutics Inc, purchase 4,650 shares at $2.21 during a trade that took place back on Mar 28 ’25, which means that Spoor Johan M. is holding 4,650 shares at $10,288 based on the most recent closing price.
Stock Fundamentals for CATX
The total capital return value is set at -0.28.
Based on Perspective Therapeutics Inc (CATX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -4.5. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1893.46.
Currently, EBITDA for the company is 10.46 million with net debt to EBITDA at 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.68.
Conclusion
To put it simply, Perspective Therapeutics Inc (CATX) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
